Bacil Pharma（524516）株式概要バシル・ファーマ社はインドで医薬品、医薬化学品、植物製品の製造、輸出、小売を行っている。 詳細524516 ファンダメンタル分析スノーフレーク・スコア評価1/6将来の成長0/6過去の実績4/6財務の健全性4/6配当金0/6報酬株価収益率（ 20.2 x） Indian市場（ 23.2 x）を下回っています。過去1年間で収益は284.9%増加しました リスク分析意味のある時価総額がありません ( ₹314M )収益が 100 万ドル未満 ( ₹0 )Indian市場と比較した過去 3 か月間の株価の変動すべてのリスクチェックを見る524516 Community Fair Values Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.NEW480,575 membersJoin community and earn perksGain real feedbackFrom our editorial team, personally. Not silence.Grow your followingReal investors. The kind who actually invest, not scroll past.Unlock free accessFree premium subscription for consistent and quality authors.Learn moreCreate NarrativeBLINRODA480,575 investors already sharing narrativesYour Fair Value₹Current Price₹21.85該当なし内在価値ディスカウントEst. Revenue$PastFuture-39m16m2016201920222025202620282031Revenue ₹1.0Earnings ₹0AdvancedSet Fair ValueView all narrativesBacil Pharma Limited 競合他社PanjonSymbol: BSE:526345Market cap: ₹303.0mGujarat Terce LaboratoriesSymbol: BSE:524314Market cap: ₹295.4mMurae OrganisorSymbol: BSE:542724Market cap: ₹353.2mGoldline PharmaceuticalSymbol: BSE:544759Market cap: ₹396.1m価格と性能株価の高値、安値、推移の概要Bacil Pharma過去の株価現在の株価₹21.8552週高値₹61.8052週安値₹21.85ベータ0.361ヶ月の変化-45.52%3ヶ月変化-61.63%1年変化-41.86%3年間の変化140.64%5年間の変化228.57%IPOからの変化648.29%最新ニュースValuation Update With 7 Day Price Move • Jul 23Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to ₹29.68, the stock trades at a trailing P/E ratio of 27.4x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 227% over the past three years.New Risk • Jul 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m. Market cap is less than US$10m (₹565.9m market cap, or US$5.96m). Minor Risk Share price has been volatile over the past 3 months (8.0% average weekly change).Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to ₹39.31, the stock trades at a trailing P/E ratio of 76.5x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 322% over the past three years.お知らせ • May 11Bacil Pharma Limited to Report Q4, 2026 Results on May 22, 2026Bacil Pharma Limited announced that they will report Q4, 2026 results on May 22, 2026New Risk • Mar 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.0% average weekly change). Shareholders have been substantially diluted in the past year (144% increase in shares outstanding). Revenue is less than US$1m (₹5.5m revenue, or US$60k). Market cap is less than US$10m (₹694.0m market cap, or US$7.59m). Minor Risk Large one-off items impacting financial results.お知らせ • Feb 05Bacil Pharma Limited to Report Q3, 2026 Results on Feb 13, 2026Bacil Pharma Limited announced that they will report Q3, 2026 results on Feb 13, 2026最新情報をもっと見るRecent updatesValuation Update With 7 Day Price Move • Jul 23Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to ₹29.68, the stock trades at a trailing P/E ratio of 27.4x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 227% over the past three years.New Risk • Jul 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m. Market cap is less than US$10m (₹565.9m market cap, or US$5.96m). Minor Risk Share price has been volatile over the past 3 months (8.0% average weekly change).Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to ₹39.31, the stock trades at a trailing P/E ratio of 76.5x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 322% over the past three years.お知らせ • May 11Bacil Pharma Limited to Report Q4, 2026 Results on May 22, 2026Bacil Pharma Limited announced that they will report Q4, 2026 results on May 22, 2026New Risk • Mar 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.0% average weekly change). Shareholders have been substantially diluted in the past year (144% increase in shares outstanding). Revenue is less than US$1m (₹5.5m revenue, or US$60k). Market cap is less than US$10m (₹694.0m market cap, or US$7.59m). Minor Risk Large one-off items impacting financial results.お知らせ • Feb 05Bacil Pharma Limited to Report Q3, 2026 Results on Feb 13, 2026Bacil Pharma Limited announced that they will report Q3, 2026 results on Feb 13, 2026New Risk • Jan 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.4% average weekly change). Shareholders have been substantially diluted in the past year (144% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (₹626.7m market cap, or US$6.94m). Minor Risk Large one-off items impacting financial results.お知らせ • Nov 05Bacil Pharma Limited to Report Q2, 2026 Results on Nov 13, 2025Bacil Pharma Limited announced that they will report Q2, 2026 results on Nov 13, 2025Valuation Update With 7 Day Price Move • Nov 03Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹32.83, the stock trades at a trailing P/E ratio of 42.6x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 394% over the past three years.お知らせ • Sep 05Bacil Pharma Limited, Annual General Meeting, Sep 29, 2025Bacil Pharma Limited, Annual General Meeting, Sep 29, 2025, at 13:00 Indian Standard Time.お知らせ • Aug 06Bacil Pharma Limited to Report Q1, 2026 Results on Aug 12, 2025Bacil Pharma Limited announced that they will report Q1, 2026 results on Aug 12, 2025Board Change • Aug 01High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Non-Executive Independent Director Avani Godhaniya is the most experienced director on the board, commencing their role in 2024. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.お知らせ • May 18Bacil Pharma Limited to Report Q4, 2025 Results on May 26, 2025Bacil Pharma Limited announced that they will report Q4, 2025 results on May 26, 2025New Risk • May 03New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 144% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (144% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (₹594.2m market cap, or US$7.03m). Minor Risks Large one-off items impacting financial results. Significant insider selling over the past 3 months (₹12m sold).Recent Insider Transactions • Mar 25Executive Director recently sold ₹7.9m worth of stockOn the 21st of March, Prakash Shah sold around 208k shares on-market at roughly ₹38.00 per share. This transaction amounted to 99% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹16m more than they bought in the last 12 months.Recent Insider Transactions • Mar 12Executive Director recently sold ₹4.1m worth of stockOn the 10th of March, Prakash Shah sold around 115k shares on-market at roughly ₹35.89 per share. This transaction amounted to 35% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹8.1m more than they bought in the last 12 months.Valuation Update With 7 Day Price Move • Feb 07Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹47.88, the stock trades at a trailing P/E ratio of 73.2x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 404% over the past three years.お知らせ • Jan 13Bacil Pharma Limited to Report Q3, 2025 Results on Jan 21, 2025Bacil Pharma Limited announced that they will report Q3, 2025 results on Jan 21, 2025お知らせ • Oct 17+ 1 more updateBacil Pharma Limited announced that it expects to receive INR 50 million in fundingBacil Pharma Limited announced a private placement to issue 1,562,500 shares at an issue price of INR 32 per share for the gross proceeds of INR 50,000,000 on October 15, 2024. The transaction will include participation from proposed public allottees (Category Non-Promoter). the transaction has been approved by shareholders and subject to approval of members of the company in the ensuing Extra-Ordinary General Meeting and other regulatory approvals from authorities.お知らせ • Oct 16Bacil Pharma Limited to Report Q2, 2025 Results on Oct 23, 2024Bacil Pharma Limited announced that they will report Q2, 2025 results on Oct 23, 2024Recent Insider Transactions • Sep 24Executive Director recently sold ₹4.0m worth of stockOn the 20th of September, Prakash Shah sold around 157k shares on-market at roughly ₹25.63 per share. This transaction amounted to 15% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.お知らせ • Sep 10Bacil Pharma Limited, Annual General Meeting, Sep 27, 2024Bacil Pharma Limited, Annual General Meeting, Sep 27, 2024, at 10:00 Indian Standard Time. Location: 71, laxmi building, 4th floor, sir p m road, fort, mumbai-400001, mumbai IndiaBoard Change • Sep 09Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 3 highly experienced directors. Independent Non-Executive Director Lalit Jain was the last director to join the board, commencing their role in 2012. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Aug 31Bacil Pharma Limited Announces Resignation Suman Prakash Shah as Non-Executive DirectorBacil Pharma Limited announced that at the board meeting held on August 31, 2024, approved resignation of Mrs. Suman Prakash Shah as Non-Executive Director of the Company with effect from August 31, 2024 due to pre-occupancy in other assignments and personal. reasons. Names of Listed Entities in which the resigning director holds directorships, indicating the category of directorship and membership of board committees, if any. 1. Directorship -Sanmitra Commercia Limited 2. Membership/Chairmanship in Board Committees- NIL.お知らせ • Aug 08Bacil Pharma Limited to Report Q1, 2025 Results on Aug 14, 2024Bacil Pharma Limited announced that they will report Q1, 2025 results on Aug 14, 2024お知らせ • May 17Bacil Pharma Limited to Report Q4, 2024 Results on May 21, 2024Bacil Pharma Limited announced that they will report Q4, 2024 results on May 21, 2024New Risk • Nov 13New major risk - Revenue and earnings growthEarnings have declined by 0.4% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 0.4% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (₹46.8m market cap, or US$561.2k).お知らせ • Nov 04Bacil Pharma Limited to Report Q2, 2024 Results on Nov 10, 2023Bacil Pharma Limited announced that they will report Q2, 2024 results on Nov 10, 2023お知らせ • Sep 15Bacil Pharma Limited Appoints Mrs. Bhavana Tak as Company Secretary and Compliance OfficerBoard of Directors of Bacil Pharma Limited at their meeting held on 14 th September, 2023 transacted the following Business: Considered and approved appointment of Mrs. Bhavana Tak (ACS No- A71532) as Company Secretary and Compliance Officer of the Company based on recommendation by Nomination and Remuneration Committee. Mrs. Bhavana Tak is a Qualified Company Secretary and having work Experience undera PCS Firm.お知らせ • Aug 25Bacil Pharma Limited, Annual General Meeting, Sep 16, 2023Bacil Pharma Limited, Annual General Meeting, Sep 16, 2023, at 14:00 Indian Standard Time. Location: 71, Laxmi Building, 4th Floor, Sir P. M. Road Fort Mumbai India Agenda: To receive, consider and adopt the Audited Financial Statements of the Company as at 31st March, 2023 and Reports of the Directors' and Auditor's thereon; to appoint a Director in place of Mr. Prakash Bhoorchand Shah who retires by rotation at this Annual General Meeting and being eligible, offers himself for re-appointment; and to consider other matter.お知らせ • Aug 08Bacil Pharma Limited to Report Q1, 2024 Results on Aug 14, 2023Bacil Pharma Limited announced that they will report Q1, 2024 results on Aug 14, 2023お知らせ • Feb 03Bacil Pharma Limited to Report Q3, 2023 Results on Feb 11, 2023Bacil Pharma Limited announced that they will report Q3, 2023 results on Feb 11, 2023Board Change • Oct 31High number of new directorsNon-Executive & Non-Independent Director Suman Shah was the last director to join the board, commencing their role in 2022.お知らせ • Sep 30Bacil Pharma Limited Appoints Suman Shah as Non-Executive Non- Independent DirectorBacil Pharma Limited appointed Suman Shah (DIN: 01764668), as Non-Executive Non- Independent Director of the Company at its AGM held on September 29, 2022.お知らせ • Sep 02Bacil Pharma Limited, Annual General Meeting, Sep 29, 2022Bacil Pharma Limited, Annual General Meeting, Sep 29, 2022. Agenda: To consider and approve re-appointment of M/s Laxmikant Kabra & Co, LLP as Statutory Auditors of the Company for the second term of Five Years from Financial Year 2022-23 up to Financial Year 2026-27; to consider and approve appointment of Mrs. Suman Shah as Non-Executive Non-Independent Director of the Company; and to consider other matters.お知らせ • May 23Bacil Pharma Limited to Report Q4, 2022 Results on May 30, 2022Bacil Pharma Limited announced that they will report Q4, 2022 results on May 30, 2022Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non-Executive Woman Director Sneha Shah was the last director to join the board, commencing their role in 2015. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Mar 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non-Executive Woman Director Sneha Shah was the last director to join the board, commencing their role in 2015. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Feb 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non-Executive Woman Director Sneha Shah was the last director to join the board, commencing their role in 2015. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.お知らせ • Feb 06Bacil Pharma Limited to Report Q3, 2022 Results on Feb 14, 2022Bacil Pharma Limited announced that they will report Q3, 2022 results on Feb 14, 2022Board Change • Sep 13Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Director Lalit Jain was the last independent director to join the board, commencing their role in 2012. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.Is New 90 Day High Low • Mar 05New 90-day low: ₹4.53The company is down 19% from its price of ₹5.60 on 04 December 2020. The Indian market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 2.0% over the same period.お知らせ • Feb 06Bacil Pharma Limited to Report Q3, 2021 Results on Feb 13, 2021Bacil Pharma Limited announced that they will report Q3, 2021 results on Feb 13, 2021Is New 90 Day High Low • Dec 31New 90-day low: ₹4.72The company is down 9.0% from its price of ₹5.20 on 01 October 2020. The Indian market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 7.0% over the same period.お知らせ • Oct 20Bacil Pharma Limited Announces Appointment of Vaishali Vaghasiya as Company Secretary and Compliance OfficerBacil Pharma Limited announced that Ms. Vaishali Vaghasiya (A-60980) a qualified member of Institute of Company Secretary of India is been appointed as Company Secretary and Compliance Officer of the company with effect from 19 October, 2020, pursuant to Section 203 of the Companies Act 2013 and Regulation 6(1) of the Securities and Exchange Board of India (Listing Obligation & Disclosure Requirements) Regulations, 2015.Is New 90 Day High Low • Sep 22New 90-day high: ₹3.74The company is up 44% from its price of ₹2.60 on 24 June 2020. The Indian market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 14% over the same period.お知らせ • Sep 12Bacil Pharma Limited to Report Q1, 2021 Results on Sep 15, 2020Bacil Pharma Limited announced that they will report Q1, 2021 results on Sep 15, 2020お知らせ • Jul 26Bacil Pharma Limited to Report Q4, 2020 Results on Jul 30, 2020Bacil Pharma Limited announced that they will report Q4, 2020 results on Jul 30, 2020株主還元524516IN PharmaceuticalsIN 市場7D-22.5%2.3%2.0%1Y-41.9%16.0%3.6%株主還元を見る業界別リターン: 524516過去 1 年間で16 % の収益を上げたIndian Pharmaceuticals業界を下回りました。リターン対市場: 524516は、過去 1 年間で3.6 % のリターンを上げたIndian市場を下回りました。価格変動Is 524516's price volatile compared to industry and market?524516 volatility524516 Average Weekly Movement7.6%Pharmaceuticals Industry Average Movement6.1%Market Average Movement6.0%10% most volatile stocks in IN Market9.0%10% least volatile stocks in IN Market3.7%安定した株価: 524516の株価は、 Indian市場と比較して過去 3 か月間で変動しています。時間の経過による変動: 524516の weekly volatility ( 8% ) は過去 1 年間安定していますが、依然としてIndianの株式の 75% よりも高くなっています。会社概要設立従業員CEO（最高経営責任者ウェブサイト19872Ganpat Salekarbacilpharma.co.inバシル・ファーマ社はインドで医薬品、医薬化学品、植物製品の製造、輸出、小売を行っている。同社は抗不安薬、抗ヒスタミン薬、化合物、医薬品、ハーブの錠剤やカプセルを提供している。バシル・ファーマ社は1987年に設立され、インドのムンバイを拠点としている。もっと見るBacil Pharma Limited 基礎のまとめBacil Pharma の収益と売上を時価総額と比較するとどうか。524516 基礎統計学時価総額₹313.61m収益（TTM）₹15.56m売上高(TTM)n/a20.2xPER（株価収益率0.0xP/Sレシオ524516 は割高か？公正価値と評価分析を参照収益と収入最新の決算報告書（TTM）に基づく主な収益性統計524516 損益計算書（TTM）収益₹0売上原価₹0売上総利益₹0その他の費用-₹15.55m収益₹15.56m直近の収益報告Mar 31, 2026次回決算日該当なし一株当たり利益（EPS）1.08グロス・マージン0.00%純利益率0.00%有利子負債／自己資本比率0%524516 の長期的なパフォーマンスは？過去の実績と比較を見るView Valuation企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/08/01 21:39終値2026/07/31 00:00収益2026/03/31年間収益2026/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレークこのレポートを生成するために使用した分析モデルの詳細は、当社のGitHubページでご覧いただけます。また、レポートの活用方法に関するガイドやYouTubeのチュートリアルも用意しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Bacil Pharma Limited 0 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。0
Valuation Update With 7 Day Price Move • Jul 23Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to ₹29.68, the stock trades at a trailing P/E ratio of 27.4x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 227% over the past three years.
New Risk • Jul 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m. Market cap is less than US$10m (₹565.9m market cap, or US$5.96m). Minor Risk Share price has been volatile over the past 3 months (8.0% average weekly change).
Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to ₹39.31, the stock trades at a trailing P/E ratio of 76.5x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 322% over the past three years.
お知らせ • May 11Bacil Pharma Limited to Report Q4, 2026 Results on May 22, 2026Bacil Pharma Limited announced that they will report Q4, 2026 results on May 22, 2026
New Risk • Mar 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.0% average weekly change). Shareholders have been substantially diluted in the past year (144% increase in shares outstanding). Revenue is less than US$1m (₹5.5m revenue, or US$60k). Market cap is less than US$10m (₹694.0m market cap, or US$7.59m). Minor Risk Large one-off items impacting financial results.
お知らせ • Feb 05Bacil Pharma Limited to Report Q3, 2026 Results on Feb 13, 2026Bacil Pharma Limited announced that they will report Q3, 2026 results on Feb 13, 2026
Valuation Update With 7 Day Price Move • Jul 23Investor sentiment deteriorates as stock falls 20%After last week's 20% share price decline to ₹29.68, the stock trades at a trailing P/E ratio of 27.4x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 227% over the past three years.
New Risk • Jul 02New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Indian stocks, typically moving 8.0% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Revenue is less than US$1m. Market cap is less than US$10m (₹565.9m market cap, or US$5.96m). Minor Risk Share price has been volatile over the past 3 months (8.0% average weekly change).
Valuation Update With 7 Day Price Move • Jun 15Investor sentiment deteriorates as stock falls 21%After last week's 21% share price decline to ₹39.31, the stock trades at a trailing P/E ratio of 76.5x. Average trailing P/E is 29x in the Pharmaceuticals industry in India. Total returns to shareholders of 322% over the past three years.
お知らせ • May 11Bacil Pharma Limited to Report Q4, 2026 Results on May 22, 2026Bacil Pharma Limited announced that they will report Q4, 2026 results on May 22, 2026
New Risk • Mar 02New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 9.0% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.0% average weekly change). Shareholders have been substantially diluted in the past year (144% increase in shares outstanding). Revenue is less than US$1m (₹5.5m revenue, or US$60k). Market cap is less than US$10m (₹694.0m market cap, or US$7.59m). Minor Risk Large one-off items impacting financial results.
お知らせ • Feb 05Bacil Pharma Limited to Report Q3, 2026 Results on Feb 13, 2026Bacil Pharma Limited announced that they will report Q3, 2026 results on Feb 13, 2026
New Risk • Jan 14New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Indian stocks, typically moving 8.4% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (8.4% average weekly change). Shareholders have been substantially diluted in the past year (144% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (₹626.7m market cap, or US$6.94m). Minor Risk Large one-off items impacting financial results.
お知らせ • Nov 05Bacil Pharma Limited to Report Q2, 2026 Results on Nov 13, 2025Bacil Pharma Limited announced that they will report Q2, 2026 results on Nov 13, 2025
Valuation Update With 7 Day Price Move • Nov 03Investor sentiment deteriorates as stock falls 17%After last week's 17% share price decline to ₹32.83, the stock trades at a trailing P/E ratio of 42.6x. Average trailing P/E is 30x in the Pharmaceuticals industry in India. Total returns to shareholders of 394% over the past three years.
お知らせ • Sep 05Bacil Pharma Limited, Annual General Meeting, Sep 29, 2025Bacil Pharma Limited, Annual General Meeting, Sep 29, 2025, at 13:00 Indian Standard Time.
お知らせ • Aug 06Bacil Pharma Limited to Report Q1, 2026 Results on Aug 12, 2025Bacil Pharma Limited announced that they will report Q1, 2026 results on Aug 12, 2025
Board Change • Aug 01High number of new and inexperienced directorsThere are 3 new directors who have joined the board in the last 3 years. The company's board is composed of: 3 new directors. No experienced directors. No highly experienced directors. Non-Executive Independent Director Avani Godhaniya is the most experienced director on the board, commencing their role in 2024. The company’s lack of experienced directors is considered a risk according to the Simply Wall St Risk Model.
お知らせ • May 18Bacil Pharma Limited to Report Q4, 2025 Results on May 26, 2025Bacil Pharma Limited announced that they will report Q4, 2025 results on May 26, 2025
New Risk • May 03New major risk - Shareholder dilutionThe company's shareholders have been substantially diluted in the past year. Increase in shares outstanding: 144% This is considered a major risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Major Risks Shareholders have been substantially diluted in the past year (144% increase in shares outstanding). Revenue is less than US$1m. Market cap is less than US$10m (₹594.2m market cap, or US$7.03m). Minor Risks Large one-off items impacting financial results. Significant insider selling over the past 3 months (₹12m sold).
Recent Insider Transactions • Mar 25Executive Director recently sold ₹7.9m worth of stockOn the 21st of March, Prakash Shah sold around 208k shares on-market at roughly ₹38.00 per share. This transaction amounted to 99% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹16m more than they bought in the last 12 months.
Recent Insider Transactions • Mar 12Executive Director recently sold ₹4.1m worth of stockOn the 10th of March, Prakash Shah sold around 115k shares on-market at roughly ₹35.89 per share. This transaction amounted to 35% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of ₹8.1m more than they bought in the last 12 months.
Valuation Update With 7 Day Price Move • Feb 07Investor sentiment improves as stock rises 21%After last week's 21% share price gain to ₹47.88, the stock trades at a trailing P/E ratio of 73.2x. Average trailing P/E is 32x in the Pharmaceuticals industry in India. Total returns to shareholders of 404% over the past three years.
お知らせ • Jan 13Bacil Pharma Limited to Report Q3, 2025 Results on Jan 21, 2025Bacil Pharma Limited announced that they will report Q3, 2025 results on Jan 21, 2025
お知らせ • Oct 17+ 1 more updateBacil Pharma Limited announced that it expects to receive INR 50 million in fundingBacil Pharma Limited announced a private placement to issue 1,562,500 shares at an issue price of INR 32 per share for the gross proceeds of INR 50,000,000 on October 15, 2024. The transaction will include participation from proposed public allottees (Category Non-Promoter). the transaction has been approved by shareholders and subject to approval of members of the company in the ensuing Extra-Ordinary General Meeting and other regulatory approvals from authorities.
お知らせ • Oct 16Bacil Pharma Limited to Report Q2, 2025 Results on Oct 23, 2024Bacil Pharma Limited announced that they will report Q2, 2025 results on Oct 23, 2024
Recent Insider Transactions • Sep 24Executive Director recently sold ₹4.0m worth of stockOn the 20th of September, Prakash Shah sold around 157k shares on-market at roughly ₹25.63 per share. This transaction amounted to 15% of their direct individual holding at the time of the trade. This was the largest sale by an insider in the last 3 months. This was the only on-market transaction from insiders over the last 12 months.
お知らせ • Sep 10Bacil Pharma Limited, Annual General Meeting, Sep 27, 2024Bacil Pharma Limited, Annual General Meeting, Sep 27, 2024, at 10:00 Indian Standard Time. Location: 71, laxmi building, 4th floor, sir p m road, fort, mumbai-400001, mumbai India
Board Change • Sep 09Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. No experienced directors. 3 highly experienced directors. Independent Non-Executive Director Lalit Jain was the last director to join the board, commencing their role in 2012. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Aug 31Bacil Pharma Limited Announces Resignation Suman Prakash Shah as Non-Executive DirectorBacil Pharma Limited announced that at the board meeting held on August 31, 2024, approved resignation of Mrs. Suman Prakash Shah as Non-Executive Director of the Company with effect from August 31, 2024 due to pre-occupancy in other assignments and personal. reasons. Names of Listed Entities in which the resigning director holds directorships, indicating the category of directorship and membership of board committees, if any. 1. Directorship -Sanmitra Commercia Limited 2. Membership/Chairmanship in Board Committees- NIL.
お知らせ • Aug 08Bacil Pharma Limited to Report Q1, 2025 Results on Aug 14, 2024Bacil Pharma Limited announced that they will report Q1, 2025 results on Aug 14, 2024
お知らせ • May 17Bacil Pharma Limited to Report Q4, 2024 Results on May 21, 2024Bacil Pharma Limited announced that they will report Q4, 2024 results on May 21, 2024
New Risk • Nov 13New major risk - Revenue and earnings growthEarnings have declined by 0.4% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Shares are highly illiquid. Earnings have declined by 0.4% per year over the past 5 years. Revenue is less than US$1m. Market cap is less than US$10m (₹46.8m market cap, or US$561.2k).
お知らせ • Nov 04Bacil Pharma Limited to Report Q2, 2024 Results on Nov 10, 2023Bacil Pharma Limited announced that they will report Q2, 2024 results on Nov 10, 2023
お知らせ • Sep 15Bacil Pharma Limited Appoints Mrs. Bhavana Tak as Company Secretary and Compliance OfficerBoard of Directors of Bacil Pharma Limited at their meeting held on 14 th September, 2023 transacted the following Business: Considered and approved appointment of Mrs. Bhavana Tak (ACS No- A71532) as Company Secretary and Compliance Officer of the Company based on recommendation by Nomination and Remuneration Committee. Mrs. Bhavana Tak is a Qualified Company Secretary and having work Experience undera PCS Firm.
お知らせ • Aug 25Bacil Pharma Limited, Annual General Meeting, Sep 16, 2023Bacil Pharma Limited, Annual General Meeting, Sep 16, 2023, at 14:00 Indian Standard Time. Location: 71, Laxmi Building, 4th Floor, Sir P. M. Road Fort Mumbai India Agenda: To receive, consider and adopt the Audited Financial Statements of the Company as at 31st March, 2023 and Reports of the Directors' and Auditor's thereon; to appoint a Director in place of Mr. Prakash Bhoorchand Shah who retires by rotation at this Annual General Meeting and being eligible, offers himself for re-appointment; and to consider other matter.
お知らせ • Aug 08Bacil Pharma Limited to Report Q1, 2024 Results on Aug 14, 2023Bacil Pharma Limited announced that they will report Q1, 2024 results on Aug 14, 2023
お知らせ • Feb 03Bacil Pharma Limited to Report Q3, 2023 Results on Feb 11, 2023Bacil Pharma Limited announced that they will report Q3, 2023 results on Feb 11, 2023
Board Change • Oct 31High number of new directorsNon-Executive & Non-Independent Director Suman Shah was the last director to join the board, commencing their role in 2022.
お知らせ • Sep 30Bacil Pharma Limited Appoints Suman Shah as Non-Executive Non- Independent DirectorBacil Pharma Limited appointed Suman Shah (DIN: 01764668), as Non-Executive Non- Independent Director of the Company at its AGM held on September 29, 2022.
お知らせ • Sep 02Bacil Pharma Limited, Annual General Meeting, Sep 29, 2022Bacil Pharma Limited, Annual General Meeting, Sep 29, 2022. Agenda: To consider and approve re-appointment of M/s Laxmikant Kabra & Co, LLP as Statutory Auditors of the Company for the second term of Five Years from Financial Year 2022-23 up to Financial Year 2026-27; to consider and approve appointment of Mrs. Suman Shah as Non-Executive Non-Independent Director of the Company; and to consider other matters.
お知らせ • May 23Bacil Pharma Limited to Report Q4, 2022 Results on May 30, 2022Bacil Pharma Limited announced that they will report Q4, 2022 results on May 30, 2022
Board Change • Apr 27Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non-Executive Woman Director Sneha Shah was the last director to join the board, commencing their role in 2015. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Mar 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non-Executive Woman Director Sneha Shah was the last director to join the board, commencing their role in 2015. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Feb 14Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 1 experienced director. 3 highly experienced directors. Non-Executive Woman Director Sneha Shah was the last director to join the board, commencing their role in 2015. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Feb 06Bacil Pharma Limited to Report Q3, 2022 Results on Feb 14, 2022Bacil Pharma Limited announced that they will report Q3, 2022 results on Feb 14, 2022
Board Change • Sep 13Less than half of directors are independentNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 2 experienced directors. 3 highly experienced directors. 2 independent directors (3 non-independent directors). Independent Non-Executive Director Lalit Jain was the last independent director to join the board, commencing their role in 2012. The following issues are considered to be risks according to the Simply Wall St Risk Model: Minority of independent directors. Insufficient board refreshment.
Is New 90 Day High Low • Mar 05New 90-day low: ₹4.53The company is down 19% from its price of ₹5.60 on 04 December 2020. The Indian market is up 17% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 2.0% over the same period.
お知らせ • Feb 06Bacil Pharma Limited to Report Q3, 2021 Results on Feb 13, 2021Bacil Pharma Limited announced that they will report Q3, 2021 results on Feb 13, 2021
Is New 90 Day High Low • Dec 31New 90-day low: ₹4.72The company is down 9.0% from its price of ₹5.20 on 01 October 2020. The Indian market is up 20% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 7.0% over the same period.
お知らせ • Oct 20Bacil Pharma Limited Announces Appointment of Vaishali Vaghasiya as Company Secretary and Compliance OfficerBacil Pharma Limited announced that Ms. Vaishali Vaghasiya (A-60980) a qualified member of Institute of Company Secretary of India is been appointed as Company Secretary and Compliance Officer of the company with effect from 19 October, 2020, pursuant to Section 203 of the Companies Act 2013 and Regulation 6(1) of the Securities and Exchange Board of India (Listing Obligation & Disclosure Requirements) Regulations, 2015.
Is New 90 Day High Low • Sep 22New 90-day high: ₹3.74The company is up 44% from its price of ₹2.60 on 24 June 2020. The Indian market is up 8.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 14% over the same period.
お知らせ • Sep 12Bacil Pharma Limited to Report Q1, 2021 Results on Sep 15, 2020Bacil Pharma Limited announced that they will report Q1, 2021 results on Sep 15, 2020
お知らせ • Jul 26Bacil Pharma Limited to Report Q4, 2020 Results on Jul 30, 2020Bacil Pharma Limited announced that they will report Q4, 2020 results on Jul 30, 2020
